Sentences with phrase «multiforme patients»

This guarded optimism is based on the phase I trial data showing an increase in overall survival of 4 - 6 months in 11 glioblastoma multiforme patients (18 - 22 months) versus the 14 - 16 months survival typically seen with the standard treatment.

Not exact matches

In 2002 scientists showed that cytomegalovirus, or CMV, was active in the brain tumors but not the surrounding healthy tissue of all 27 patients they tested who had glioblastoma multiforme.

For patients with glioblastoma multiforme, the vaccine did not seem to prevent the recurrence of cancer, so those patients were offered follow - up chemotherapy.

The data suggests that the upregulation of MMP2 resulting from decreased Id4 expression in glioblastoma multiforme (GBM) may contribute to the morbidity and mortality of GBM patients.

Trial # 1: A phase I / II trial of HCQ in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

This compares with 14 months for patients with glioblastoma multiforme — a complex and aggressive astrocytoma.

The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.

The researchers are currently enrolling patients with stage 4 lung cancer and will soon begin enrolling people with glioblastoma multiforme (brain cancer) in these phase II trials.

The cost per patient above standard insurance billing for the phase II vitamin C glioblastoma multiforme protocol is approximately $ 8000 spread over 9 months of test infusions.

Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of thPatients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of thpatients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of the trial.

A phase I / II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.

Whereas, a phase I / II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme led to no significant improvement in overall survival, which could be due to inconsistent autophagy inhibition in patients treated with this regimen [29].

Glioblastoma multiforme (GBM) is considered the most malignant of primary brain cancers with only about 12 % of patients living beyond 36 months (long - term survivors).

These preclinical studies have led to a clinical trial for patients with glioblastoma multiforme (www.clinicaltrials.gov NCT02046187).

Background ImmunoCellular Therapeutics is a California - based oncology firm with the lead candidate ICT - 107 entering Phase II for patients with a particular form of brain cancer, glioblastoma multiforme (GBM).